TY - JOUR
T1 - Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation
AU - Winston, Drew J.
AU - Yeager, Andrew M.
AU - Chandrasekar, Pranatharthi H.
AU - Snydman, David R.
AU - Bo Petersen, Finn
AU - Territo, Mary C.
AU - Bartoni, Kathy
AU - Miller, Ken
AU - Schenkein, David
AU - Stiff, Patrick
AU - Mattison, Reid
AU - Laughlin, Mary
AU - Rybka, Witold
AU - De Magalhaes-Silverman, Margarida
AU - Wingard, John R.
AU - Mazzuli, Toni
AU - Brennan, Clare
AU - McDermott, Sharon
AU - Vargas, Mauricio
AU - Lee, Ira C.
PY - 2003/3/15
Y1 - 2003/3/15
N2 - In this multicenter, randomized study, cytomegalovirus (CMV)-seropositive patients who received an allogeneic bone marrow transplant were provided high-dose intravenous acyclovir (500 mg/m2 q8h) from the day of transplantation until engraftment. The patients were then randomly assigned to receive either oral valacyclovir, 2 g q.i.d. (n = 83), or intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week (n = 85), until day 100 after transplantation. CMV infection occurred in 12% of the patients who received valacyclovir and in 19% of the patients who received ganciclovir (hazard ratio [HR], 1.042; 95% confidence interval [CI], 0.391-2.778; P = .934). CMV disease developed in only 2 patients who received valacyclovir and in 1 patient who received ganciclovir (HR, 1.943; 95% CI, 0.176-21.44; P = .588). Oral valacyclovir can be an effective alternative to intravenous ganciclovir for prophylaxis of CMV disease after bone marrow transplantation.
AB - In this multicenter, randomized study, cytomegalovirus (CMV)-seropositive patients who received an allogeneic bone marrow transplant were provided high-dose intravenous acyclovir (500 mg/m2 q8h) from the day of transplantation until engraftment. The patients were then randomly assigned to receive either oral valacyclovir, 2 g q.i.d. (n = 83), or intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week (n = 85), until day 100 after transplantation. CMV infection occurred in 12% of the patients who received valacyclovir and in 19% of the patients who received ganciclovir (hazard ratio [HR], 1.042; 95% confidence interval [CI], 0.391-2.778; P = .934). CMV disease developed in only 2 patients who received valacyclovir and in 1 patient who received ganciclovir (HR, 1.943; 95% CI, 0.176-21.44; P = .588). Oral valacyclovir can be an effective alternative to intravenous ganciclovir for prophylaxis of CMV disease after bone marrow transplantation.
UR - http://www.scopus.com/inward/record.url?scp=0037444029&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037444029&partnerID=8YFLogxK
U2 - 10.1086/367836
DO - 10.1086/367836
M3 - Article
C2 - 12627359
AN - SCOPUS:0037444029
SN - 1058-4838
VL - 36
SP - 749
EP - 758
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 6
ER -